Clinical, Molecular, and Prognostic Significance of WHO Type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and Various Other 3q Abnormalities in Acute Myeloid Leukemia

Author:

Lugthart Sanne1,Gröschel Stefan1,Beverloo H. Berna1,Kayser Sabine1,Valk Peter J.M.1,van Zelderen-Bhola Shama Lydia1,Jan Ossenkoppele Gert1,Vellenga Edo1,van den Berg-de Ruiter Eva1,Schanz Urs1,Verhoef Gregor1,Vandenberghe Peter1,Ferrant Augustin1,Köhne Claus-Henning1,Pfreundschuh Michael1,Horst Heinz A.1,Koller Elisabeth1,von Lilienfeld-Toal Marie1,Bentz Martin1,Ganser Arnold1,Schlegelberger Brigitte1,Jotterand Martine1,Krauter Jürgen1,Pabst Thomas1,Theobald Matthias1,Schlenk Richard F.1,Delwel Ruud1,Döhner Konstanze1,Löwenberg Bob1,Döhner Hartmut1

Affiliation:

1. From Erasmus University Medical Center, Rotterdam; Free University Medical Center, Amsterdam; University Medical Center Groningen, Groningen, the Netherlands; University Hospital Ulm, Ulm; Klinik für Onkologie und Hämatologie, Städtische Kliniken Oldenburg, Oldenburg; Klinik für Innere Medizin I, Universitätskliniken des Saarlandes, Homburg; Medizinische Klinik und Poliklinik III, Universitätsklinikum Schleswig-Holstein, Kiel; Medizinische Klinik und Poliklinik III, Universitätsklinikum Bonn, Bonn;...

Abstract

PurposeAcute myeloid leukemia (AML) with inv(3)(q21q26.2)/t(3;3)(q21;q26.2) [inv(3)/t(3;3)] is recognized as a distinctive entity in the WHO classification. Risk assignment and clinical and genetic characterization of AML with chromosome 3q abnormalities other than inv(3)/t(3;3) remain largely unresolved.Patients and MethodsCytogenetics, molecular genetics, therapy response, and outcome analysis were performed in 6,515 newly diagnosed adult AML patients. Patients were treated on Dutch-Belgian Hemato-Oncology Cooperative Group/Swiss Group for Clinical Cancer Research (HOVON/SAKK; n = 3,501) and German-Austrian Acute Myeloid Leukemia Study Group (AMLSG; n = 3,014) protocols. EVI1 and MDS1/EVI1 expression was determined by real-time quantitative polymerase chain reaction.Results3q abnormalities were detected in 4.4% of AML patients (288 of 6,515). Four distinct groups were defined: A: inv(3)/t(3;3), 32%; B: balanced t(3q26), 18%; C: balanced t(3q21), 7%; and D: other 3q abnormalities, 43%. Monosomy 7 was the most common additional aberration in groups (A), 66%; (B), 31%; and (D), 37%. N-RAS mutations and dissociate EVI1 versus MDS1/EVI1 overexpression were associated with inv(3)/t(3;3). Patients with inv(3)/t(3;3) and balanced t(3q21) at diagnosis presented with higher WBC and platelet counts. In multivariable analysis, only inv(3)/t(3;3), but not t(3q26) and t(3q21), predicted reduced relapse-free survival (hazard ratio [HR], 1.99; P < .001) and overall survival (HR, 1.4; P = .006). This adverse prognostic impact of inv(3)/t(3;3) was enhanced by additional monosomy 7. Group D 3q aberrant AML also had a poor outcome related to the coexistence of complex and/or monosomal karyotypes and cryptic inv(3)/t(3;3).ConclusionVarious categories of 3q abnormalities in AML can be distinguished according to their clinical, hematologic, and genetic features. AML with inv(3)/t(3;3) represents a distinctive subgroup with unfavorable prognosis.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Cited by 206 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3